November 24th 2021
Bijal Shah, MD, MS, and Michael Wang, MD, discuss the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.
Bijal Shah, MD, MS, and Michael Wang, MD, discuss the challenges of managing high-risk mantle cell lymphoma.
Bijal Shah, MD, MS, and Michael Wang, MD, discuss navigating the referral process for CAR T-cell therapy in hematologic malignancies.
Bijal Shah, MD, MS, and Michael Wang, MD, discuss management strategies for CAR T-cell therapy–related cytokine release syndrome and neurotoxicity in leukemia and lymphoma.
Bijal Shah, MD, MS, and Michael Wang, MD, discuss the main CAR T-cell therapy–associated toxicities in hematologic malignancies.